EMA Authorised: Xtandi (enzalutamide) — Astellas Pharma Europe B.V.

View source ↗

Summary

Authorisation granted for Xtandi (enzalutamide) by EMA for prostatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Astellas Pharma Europe B.V.. Decision date: 12/02/2026